Analysts Go Head-to-Head On Ionis Pharmaceuticals - Is The Stock Poised For A 10.89% Surge?

In the latest quarter, a total of 13 analysts have provided their ratings for Ionis Pharmaceuticals (NASDAQ:IONS), showcasing a mix of bullish and bearish perspectives. Here's a breakdown of their recent ratings, highlighting how sentiments have evolved over the past 30 days and comparing them to the preceding months.

Over the past month, analysts' ratings have ranged from Bullish to Bearish, providing a snapshot of their overall sentiment. In a summary of the ratings provided, 2 analysts maintained a Bullish stance, 3 displayed Somewhat Bullish sentiments, 6 were Indifferent, 1 rated Somewhat Bearish, and 1 maintained a Bearish stance. This mixture of sentiments suggests that the analysts have varying views on Ionis Pharmaceuticals' stock performance.

Analysts have also recently evaluated Ionis Pharmaceuticals, providing 12-month price targets. The average target is $61.08, with a high estimate of $75.00 and a low estimate of $37.00. This upward trend is evident, with the current average reflecting a 10.89% increase from the previous average price target of $55.08. This indicates a shift in analysts' perception of the stock as the company progresses through the year.

The standing of Ionis Pharmaceuticals among financial experts becomes clear with a thorough analysis of recent analyst actions. A summary of key analysts, their recent evaluations, and adjustments to ratings and price targets highlights their thoughts on Ionis Pharmaceuticals. Notable actions include:

- Luca Issi of RBC Capital maintains the Outperform rating, with a price target of $70.00.

- Jessica Fye of JP Morgan raises the rating to Neutral, with a price target of $55.00.

- Debjit Chattopadhyay of Guggenheim raises the rating to Buy, with a price target of $70.00.

- Salveen Richter of Goldman Sachs raises the rating to Sell, with a price target of $37.00.

- Gena Wang of Barclays raises the rating to Equal-Weight, with a price target of $51.00.

- Joseph Stringer of Needham maintains the Buy rating, with a price target of $60.00.

- Kostas Biliouris of BMO Capital lowers the rating to Market Perform, with a price target of $60.00.

- Mani Foroohar of Leerink Partners raises the rating to Outperform, with a price target of $62.00.

- Yaron Werber of TD Cowen raises the rating to Buy, with a price target of $59.00.

- Jason Gerberry of B of A Securities raises the rating to Buy, with a price target of $68.00.

- Akash Tewari of Jefferies raises the rating to Buy, with a price target of $75.00.

These actions reflect analysts' adaptations to changing market conditions and company performance. Their evaluations demonstrate a thorough analysis of Ionis Pharmaceuticals, highlighting their perception of the company's future performance.